［1］ Lipinski C A. Drug like properties and the causes of poor solubility and poor permeability［J］. J Pharmacol Toxicol Methods, 2000, 44 (1): 235-249.

［2］ Rao G C, Kumar M S, Mathivanan N, et al. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems［J］. Pharmazie, 2004, 59(1): 5-9.

［3］ Patravale V B, Date A A, Kulkarni R M. Nanosuspensions: a promising drug delivery strategy［J］. J Pharm Pharmcol, 2004, 56(7): 827-840.

［4］ Cornelia M K, Rainer H M. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation［J］. Eur J PharmBiopharm, 2006, 62(1): 3-16.

［5］ 钱 帅, 张建军, 高 缘, 等. 纳米混悬剂研究进展［J］. 药学进展, 2007, 31(1): 9-14.

［6］ 朱建芬, 吴祥根. 纳米混悬剂的制备方法及在药剂学中应用研究进展［J］. 中国医药工业杂志, 2006, 37(3): 196-200.

［7］ Indrajit G, Sonali B, Radha V, et al. Nanosuspension for improving the bioavailability of a poor soluble drug and screening of stabilizing agents to inhibit crystal growth［J］. Int J Pharm, 2011, 409(1-2): 260-268.

［8］ Xiong R, Lu W, Li J, et al. Preparation and characterization of intravenously injectable nimodipine nanosuspension［J］. Int J Pharm, 2008, 350(1-2): 338-343.

［9］ Swarnali D, Mpharm, Suresh PK, et al. Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B［J］. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7(2) : 242-247.

［10］ Shin M S, Lee Y, Kim H, et al. Method for preparing nanoparticles comprising vitamin K and poly-isopropyl-butyl methacrylate-acrylic acid copolymer with supercritical fluid using molecular association theory : US,20080152715(AI) ［P］, 2008-06-26.

［11］ Mishra P R, Shaal L A, Müller R H, et al. Production and characterization of hesperetin nanosuspensions for dermal delivery［J］. Int J Pharm, 2009, 371(1-2): 182-189.

［12］ 陈 莉, 汤 忞, 陆伟根. 纳米混悬剂粒径稳定性及其控制策略［J］. 世界临床药物, 2010, 31(4): 245-247.

［13］ Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs［J］. Int J Pharm, 2006, 312(1-2): 179-186.

［14］ Carstensen J T. Advanced Pharmaceutical Solids［M］. NewYork: Marcel Dekker, 2001：45.

［15］ 熊若兰, 陆伟根. 纳米混悬剂研究进展［J］. 世界临床药物2007, 8(2): 117-121.

［16］ Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects ［J］. Adv Drug Deliv Rev, 2008, 60(8): 939-954.

［17］ Kesisoglou F, Panmai S, Wu Y. Nanosizing--oral formulation development and biopharmaceutical evaluation ［J］. Adv Drug Deliv Rev, 2007, 59(7): 631-644.

［18］ Trickler W J, Nagvekar A A, Dash A K. A Novel Nanoparticle Formulation for Sustained Paclitaxel Delivery ［J］. AAPS PharmSciTech, 2008, 9(2): 486-493.

［19］ 田治科. 西罗莫斯新制剂的制备及体内药物动力学研究［D］. 浙江大学, 2005：45.

［20］ 王 勤, 顾王文. 应用纳米技术增加难溶性药物吸收的研究进展［J］. 药学服务与研究, 2009, 9(1): 48-51.

［21］ 张 栋. 依托泊苷白蛋白纳米混悬剂的研究［D］. 山东大学, 2011：78-79.

［22］ Kayser O, Olbrich C, Yardley V, et al. Formulation of ampho-tericin B as nanosuspension for oral administration［J］. Int J Pharm, 2003, 254(1): 73-75.

［23］ Peters K, Leitzke S, Diederichs J E, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium aviuminfection［J］. J Antimicrob Chemother, 2000, 45(1): 77-83.

［24］ She Z Y, Ke X, Ping Q N, et al. Preparation of Breviscapine Nanosuspension and its Pharmacokinetic Behavior in Rats［J］. china journal of natural medicines, 2007, 5(1): 50-55.

［25］ Wang Y, Zhang D, Liu Z, et al. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery［J］. Nanotechnology, 2011, 21(15): 1-12.

［26］ 付 强, 孙 进, 何仲贵. 纳米结晶的研究进展［J］. 沈阳药科大学学报, 2010, 27(12):933-960.

［27］ Scholer N, Krause K, Kayser O, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a newmurine model of reactivated toxoplasmosis［J］. Antimicrob Agents Chemother, 2001, 45(6): 1771-1779.

［28］ Muller R H, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future［J］. Adv Drug DelivRev, 2001, 47(1): 3-19.

［29］ Patricia V A. Nanotechnology advances in drug delivery［J］. PharmTechnol, 2007, 31(48): 50-52.